Pharmaceutical

Ocaliva approval in Europe withdrawn following data re-assessment

Advanz Pharma, Ocaliva’s manufacturer, said thousands of patients will no longer benefit from the treatment.

Sep 4, 2024 - 04:00
Ocaliva approval in Europe withdrawn following data re-assessment
Advanz Pharma, Ocaliva’s manufacturer, said thousands of patients will no longer benefit from the treatment.
Read the original article

Tags:

Previous Article

RegenxBio touts positive data for rare disease drug RGX-121

Next Article

Skyline wins orphan drug designation for retinitis pigmentosa gene therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: In major test for prime editing, scientists successfully correct mutations in monkeys

STAT+: In major test for prime editing, scientists succ...

Oct 28, 2023

Takeda and BMC partner to decarbonise US healthcare sector

Takeda and BMC partner to decarbonise US healthcare sector

Oct 26, 2024

STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya

STAT+: Pharmalittle: Novo Nordisk to spend $6 billion t...

Nov 11, 2023